|
Soluprin Pharmaceuticals, Inc. |
|
|
150 Motor Parkway, Suite 401
Hauppauge, NY 11788
phone:631-439-6800
fax:
|
|
| Symbol |
|
| Exchange |
|
| Founded |
0 |
| Employees |
6 |
|
|
|
|
|
|
|
 |
| Summary Description |
| Intravenous, sublingual, neutral aspirin formulation |
|
| Management |
| Stan Yakatan, Chairman; Phil Felice, MD, President and CMO;
Harry Brittan, PhD, CSO |
| |
|
|
|
|
|
|
| Recent Results |
| with 3 years several hundred dollars |
| |
|
|
| Keywords |
| pain
cardiovascular disease
veterinary applications
intravenous
sublingual
otc
women health
deep vein thrombosis |
|
|
|
| Description |
|
Soluprin Pharmaceuticals Inc (SPI) was founded to provide the medical community with a novel, intravenous, and sublingual aspirin formulation that will overcome the traditional limitations related to the use of aspirin in clinical settings. There are clear unmet clinical needs in the global market for improved efficacy, safety, and tolerability of aspirin, including in situations involving gastrointestinal ulcers and perforation, stomach bleeding, and tinnutis. SPI's novel formulation is completely soluble in water; has a neutral PH, in contrast with existing aspirin formulations, which are highly acetic; is expected to have a significantly enhanced safety profile as it relates to internal bleeding; has a very rapid speed of absorption; and is expected to have a median platelet inhibition time that is much shorter than that of conventional aspirin. The Company believes that its product, SOLUPRIN, will be the first intravenous aspirin formulation the receive FDA approval via the 505(b)(2) approval pathway. SPI has developed a strategy that will focus on commercialization in five major markets: pain, cardiovascular disease, chronic migraine, premenstrual syndrome, and the veterinary markets. This earlier-stage biotechnology company is raising $4-5M to complete animal and human trials. |
|
| Products / Services |
over the counter aspirin formulation
sublingual soluble aspirin formulation
intravenous soluble aspirin formulation
IV drip soluble aspirin formulation
|
|
| Market / Customers |
market size several billion
virtually every analgesic
but there are no truly soluble aspirin available today in an intravenous form.
|
|
| Competitors / Substitutes / Alternatives |
in europe dispirin.. asproclear aspegisic non can be sold in the usa due to FDA restrictions
|
|
| Strategy |
to complete clinical trial 505b2 then partner by inidication and geographic markets
|
|
| Funding |
| seeking 4-5 million to complete human trials. |
|
| Status |
| ready to start manufactering and begin trials in first quarter |
|
|
|
| |
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members